Peripheral proinflammatory markers associated with ketamine response in a preclinical model of antidepressant-resistance

Behavioural Brain Research

Volumn 293, Issue , 2015, Pages 198-202

  Walker, Adam J ^a,b   Foley, Brittany M ^a,c   Sutor, Shari L ^a   McGillivray, Jane A ^b   Frye, Mark A ^a   Tye, Susannah J ^a,b,d,e  

^a MAYO CLINIC   (United States)

^b DEAKIN UNIVERSITY   (Australia)

^c UNIVERSITY OF SAN DIEGO   (United States)

^d MAYO GRADUATE SCHOOL   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Adrenocorticotropic hormone (ACTH); Animal model; C reactive protein (CRP); Cytokine; Ketamine; Treatment resistant depression (TRD)

Indexed keywords

C REACTIVE PROTEIN; CORTICOTROPIN; INTERLEUKIN 6; KETAMINE; SODIUM CHLORIDE; TRICYCLIC ANTIDEPRESSANT AGENT; TUMOR NECROSIS FACTOR ALPHA; ANTIDEPRESSANT AGENT; CYTOKINE;

ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FORCED SWIM TEST; IMMOBILITY; MALE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; ANALYSIS OF VARIANCE; ANIMAL; DEPRESSION; DISEASE MODEL; DRUG EFFECTS; EXPLORATORY BEHAVIOR; METABOLISM; MOTOR ACTIVITY; PRECLINICAL STUDY; SWIMMING; TONIC IMMOBILITY; WISTAR RAT;

ADRENOCORTICOTROPIC HORMONE; ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; C-REACTIVE PROTEIN; CYTOKINES; DEPRESSION; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXPLORATORY BEHAVIOR; IMMOBILITY RESPONSE, TONIC; KETAMINE; MALE; MOTOR ACTIVITY; RATS; RATS, WISTAR; SWIMMING;

EID: 84938371126     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2015.07.026     Document Type: Article

References (15)

1. Audet M.C., Anisman H. Interplay between pro-inflammatory cytokines and growth factors in depressive illnesses. Front. Cell. NeuroscI. 2013, 7:68.
2. Duman R.S. Neurobiology of stress, depression, and rapid acting antidepressants: remodeling synaptic connections. Depress. Anxiety 2014, 31:291-296.
3. Kitamura Y., Araki H., Gomita Y. Influence of ACTH on the effects of imipramine, desipramine and lithium on duration of immobility of rats in the forced swim test. Pharmacol. Biochem. Behav. 2002, 71:63-69.
4. Li N., Lee B., Liu R.J., Banasr M., Dwyer J.M., Iwata M., Li X.Y., Aghajanian G., Duman R.S. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
5. Maes M., Fisar Z., Medina M., Scapagnini G., Nowak G., Berk M. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates-Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 2012, 20:127-150.
6. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 2009, 65:732-741.
7. Penninx B.W., Milaneschi Y., Lamers F., Vogelzangs N. Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile. BMC Med. 2013, 11:129.
8. Raison C.L., Rutherford R.E., Woolwine B.J., Shuo C., Schettler P., Drake D.F., Haroon E., Miller A.H. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013, 70:31-41.
9. Rush A.J. Ketamine for treatment-resistant depression: ready or not for clinical use?. Am. J. Psychiatry 2013, 170:1079-1081.
10. Scheller J., Chalaris A., Schmidt-Arras D., Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochem. Biophys. Acta 2011, 1813:878-888.
11. Sigalas P.D., Garg H., Watson S., McAllister-Williams R.H., Ferrier I.N. Metyrapone in treatment-resistant depression. Ther. Adv. Psychopharmacol. 2012, 2:139-149.
12. Stetler C., Miller G.E. Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. Psychosom. Med. 2011, 73:114-126.
13. Tuchscherer M., Kanitz E., Puppe B., Tuchscherer A. Altered immunomodulation by glucocorticoids in neonatal pigs exposed to a psychosocial stressor. Pediatr. Res. 2010, 68:473-478.
14. Walker A.J., Burnett S.A., Hasebe K., McGillivray J.A., Gray L.J., McGee S.L., Walder K., Berk M., Tye S.J. Chronic adrenocorticotrophic hormone treatment alters tricyclic antidepressant efficacy and prefrontal monoamine tissue levels. Behav. Brain Res. 2013, 242:76-83.
15. Zunszain P.A., Horowitz M.A., Cattaneo A., Lupi M.M., Pariante C.M. Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties. Mol. Psychiatry 2013, 18:1236-1241.